权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A Quantitative Multiplexed Platform for the Pharmacogenomic Analysis of Lung Cancer

用于肺癌药物基因组学分析的定量多重平台

基本信息

批准号：
9155816
负责人：
Dmitri Petrov
金额：
$ 55.44万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-05 至 2019-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9155816
关键词：
Alleles Biological Models Cancer Etiology Cell Culture System Cell Line Cessation of life Clinic Clinical Clinical Research Clinical Treatment Clinical Trials Clinical Trials Design Clustered Regularly Interspaced Short Palindromic Repeats Data Development Environment Frequencies Gene Silencing Generations Genetic Genetic Engineering Genetically Engineered Mouse Genome engineering Genomics Genotype Goals Growth Growth Factor Receptors Health High-Throughput Nucleotide Sequencing Human Immune system Immunotherapy In Vitro Individual Investigation Lentivirus Vector Link Lung Adenocarcinoma Lung Neoplasms Malignant Neoplasms Malignant neoplasm of lung Maps Mediating Methods Modeling Mus Patients Pharmaceutical Preparations Pharmacogenomics Positioning Attribute Research Personnel Site Staging System Techniques Testing Time Translating Transplantation Tumor Suppressor Genes Tumor Suppressor Proteins Tumor-Suppressor Gene Inactivation Validation Woman Xenograft Model Xenograft procedure base cancer care cancer cell cancer genetics cancer genome cancer therapy cancer type cost cost effective flexibility genome editing genome sequencing in vivo innovation mathematical methods men mouse model novel novel strategies oncology pre-clinical pre-clinical therapy response screening targeted treatment translational study treatment response tumor vector

项目摘要

PROJECT SUMMARY Lung cancer is a major health burden, leading to more deaths than the next four major cancer types combined. Despite advances in clinical cancer genome sequencing and the development of many targeted therapies, understanding the relationship of tumor genotype to therapeutic response remains a major obstacle to translating existing drugs into effective cancer treatments in the clinic. Pharmacogenomic analysis of tumor response is often extrapolated from the analysis of patients' tumor responses or modeled using in vitro cultured cell line systems, but investigating the effect of tumor genotype on drug response in cell lines, patient-derived xenograft models, or patients themselves all have severe limitations. Genetically-engineered mouse models have emerged as particularly rigorous in vivo systems with which to test early stage oncology therapies and represent tractable models with which to investigate the impact of tumor genotype on therapy response. Current genetically-engineered mouse models are time-consuming, cost-intensive, and have unavoidable technical and experimental variability that has limited their use in translational studies. We have established a novel multiplexed somatic genome-editing approach that will allow the quantification of genotype-specific drug responses. This in vivo approach will increase in precision and scope of translational cancer pharmacogenomics studies. To quantify the effect of tumor suppressor gene inactivation on lung cancer growth, we established a system that combines somatic Cas9-mediated gene inactivation with existing genetically-engineered mouse models to generate ~30 different lung tumor genotypes. To quantify the exact size of each tumor and determine the size distribution of each tumor genotype, we induce tumors with barcoded vectors and use high-throughput sequencing and statistical approaches to determine the number of cancer cells in each tumor. We will combine our quantitative pooled genome-editing approach with pre-clinical treatments to uncover genotype-specific therapy responses. We will quantify the responses of ~30 different genotypes of tumors to several therapies that have been shown to have genotype-specific effects in lung adenocarcinoma models. This will extend our understanding of the genomic modifiers of treatment responses and define the experimental and statistical parameters to enable the most efficient use of these models for translational studies. Finally, by performing pre-clinical/co-clinical trials for targeted therapies across >30 tumor genotypes in parallel we will generate a pharmacogenomic map connecting lung adenocarcinoma genotype to targeted therapy response. Our ongoing clinical interactions will allow validation of our pharmacogenomic predictions in lung adenocarcinoma patients. This flexible system can incorporate additional tumor suppressors, allows for the investigation of genotype-specific responses to other therapies including immunotherapies, and be adapted to other cancer types. The techniques described in this proposal are ideally positioned to become a mainstay of pre-clinical/co-clinical trial design.

项目总结